| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Allarity Therapeutics Inc. | IXEMPRA | Metastatic breast cancer (mBC) | Phase 2 | Trial Discontinued | Intravenous | Oncology |
| Allarity Therapeutics Inc. | Stenoparib in combination with temozolomide | Small Cell Lung Cancer (SCLC) | Phase 2 | Trial Planned | Oral | Oncology |
| Allena Pharmaceuticals Inc. | Reloxaliase ALLN-177 (Study 206) | Primary hyperoxaluria | Phase 2 | Oral | Genetic Disorder | |
| Allena Pharmaceuticals Inc. | Reloxaliase (ALLN-177) - (URIROX-2) | Enteric Hyperoxaluria | Phase 3 | Oral | Gastroenterology | |
| Allena Pharmaceuticals Inc. | ALLN-346-202 | Gout in chronic kidney disease (CKD) | Phase 2a | Oral | N/A | |
| Allena Pharmaceuticals Inc. | Reloxaliase (ALLN-177) - (URIROX-2) | Enteric Hyperoxaluria | Phase 3 | Oral | Gastroenterology | |
| Allena Pharmaceuticals Inc. | Reloxaliase ALLN-177 (URIROX-1) | Enteric Hyperoxaluria | Phase 3 | Oral | Gastroenterology | |
| Allena Pharmaceuticals Inc. | Reloxaliase ALLN-177 (URIROX-1) | Enteric Hyperoxaluria | Phase 3 | Oral | Gastroenterology |